|
rs2046210
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
|
rs4415084
|
|
|
0.010 |
GeneticVariation |
BEFREE |
After grouping breast cancer subtypes, significantly reduced survival was associated with the variant alleles of rs9485372 for luminal A and rs4415084 for triple negative breast cancer.
|
30285756 |
2018 |
|
rs4849887
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs718282
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of the XRCC2 gene -41657C/T (rs718282) and of the RAD51 gene, -172G/T (rs1801321), were investigated by PCR-RFLP in 70 patients with triple-negative breast cancer and 70 age- and sex matched non-cancer controls.
|
25743260 |
2015 |
|
rs12075
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study suggested that rs12075 could be served as a key predictive factor of recurrence risk in breast cancer, especially for TNBC subtype.
|
30358125 |
2018 |
|
rs2814778
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Frequency of the Duffy-null allele (rs2814778; an African ancestral variant adopted under selective pressure as protection against malaria) was associated with TNBC-specific risk (P < 0.0001), quantified West African Ancestry (P < 0.0001) and was more common in AA, Ghanaians, and TNBC cases.
|
31356281 |
2019 |
|
rs2363956
|
|
|
0.020 |
GeneticVariation |
BEFREE |
Additionally, rs4849887 was significantly associated with overall BC risk, and both rs2363956 and rs13000023 were associated with TNBC-specific risk, although none as strongly as the Duffy-null variant.
|
31356281 |
2019 |
|
rs2363956
|
|
|
0.020 |
GeneticVariation |
BEFREE |
The five SNPs were also associated with triple-negative breast cancer in a separate study of 2,301 triple-negative cases and 3,949 controls (P(trend) = 1 × 10⁻⁷) to P(trend) = 8 × 10⁻⁵; rs2363956 per-allele OR = 0.80, 95% CI 0.74-0.87, P(trend) = 1.1 × 10⁻⁷
|
20852631 |
2010 |
|
rs527616
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Our study is aimed to evaluate the prognostic value of the genome wide association study (GWAS)-identified CHST9 rs1436904 and AQP4 rs527616 genetic variants in our established early-stage TNBC sample database.
|
28924212 |
2017 |
|
rs473543
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ATG5 rs473543 genotypes may serve as a potential marker for predicting recurrence of early-stage TNBC patients who received anthracycline-and/or taxane-based regimens as adjuvant chemotherapy.
|
29382381 |
2018 |
|
rs8170
|
|
|
0.020 |
GeneticVariation |
BEFREE |
In addition, a combined analysis of triple-negative cases from BCAC and the Triple Negative Breast Cancer Consortium (TNBCC; N = 3,566) identified a genome-wide significant association between rs8170 and triple-negative breast cancer risk (OR, 1.25; 95% CI, 1.18-1.33; P = 3.31 × 10(-13)].
|
22331459 |
2012 |
|
rs8170
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified six single-nucleotide polymorphisms, including rs2046210 (ESR1), rs12662670 (ESR1), rs3803662 (TOX3), rs999737 (RAD51L1), rs8170 (19p13.1), and rs8100241 (19p13.1), significantly associated with the risk of triple-negative breast cancer.
|
21844186 |
2011 |
|
rs2278256
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In addition, the haplotypes containing two polymorphisms rs7250266 and rs2278256 are associated with a lower chance of TNBC development specifically.
|
26848770 |
2016 |
|
rs7250266
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We found that rs7250266 in the promoter region of NBA1 confers a decreased risk to TNBC development, but not to non-TNBC</span> susceptibility.
|
26848770 |
2016 |
|
rs587780021
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found four good candidate pathogenic BARD1 mutations in the TNBC cohort, including two protein-truncating mutations (p.Gln564Ter and p.Arg641Ter).
|
26010302 |
2016 |
|
rs587781948
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found four good candidate pathogenic BARD1 mutations in the TNBC cohort, including two protein-truncating mutations (p.Gln564Ter and p.Arg641Ter).
|
26010302 |
2016 |
|
rs1064793309
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a result of a routine BRCA1/BRCA2 mutational screening, we identified a previously unreported BRCA1 sequence alteration [c.5178G>A (V1687I)] in a patient diagnosed with early onset triple negative breast cancer.
|
22527099 |
2012 |
|
rs4986850
|
|
|
0.010 |
GeneticVariation |
BEFREE |
However, the D693N SNP was associated with the risk of triple negative breast cancer (odds ratio = 2.31 95% confidence interval 1.08-4.93).
|
23674270 |
2013 |
|
rs772885662
|
|
|
0.010 |
GeneticVariation |
BEFREE |
As a result of a routine BRCA1/BRCA2 mutational screening, we identified a previously unreported BRCA1 sequence alteration [c.5178G>A (V1687I)] in a patient diagnosed with early onset triple negative breast cancer.
|
22527099 |
2012 |
|
rs799917
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Associations between the rs799917 polymorphism and progression risk were investigated after genotyping 370 TNBC patients.
|
28744749 |
2017 |
|
rs80356898
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We also found four good candidate pathogenic BARD1 mutations in the TNBC cohort, including two protein-truncating mutations (p.Gln564Ter and p.Arg641Ter).
|
26010302 |
2016 |
|
rs80357367
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In Fanconi anemia complementation gene M (FANCM), nonsense mutation c.5101C>T (p.Q1701X) was significantly more frequent among breast cancer patients than among controls [odds ratio (OR) = 1.86, 95% CI = 1.26-2.75; P = 0.0018], with particular enrichment among patients with triple-negative breast cancer (TNBC; OR = 3.56, 95% CI = 1.81-6.98, P = 0.0002).
|
25288723 |
2014 |
|
rs8176318
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A germline, variant in the BRCA1 3'UTR (rs8176318) was previously shown to predict breast and ovarian cancer risk in women from high-risk families, as well as increased risk of triple negative breast cancer.
|
24915755 |
2014 |
|
rs397507758
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In Fanconi anemia complementation gene M (FANCM), nonsense mutation c.5101C>T (p.Q1701X) was significantly more frequent among breast cancer patients than among controls [odds ratio (OR) = 1.86, 95% CI = 1.26-2.75; P = 0.0018], with particular enrichment among patients with triple-negative breast cancer (TNBC; OR = 3.56, 95% CI = 1.81-6.98, P = 0.0002).
|
25288723 |
2014 |
|
rs552752779
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Whole exome sequencing in triple negative breast cancer cases (n = 8) and targeted sequencing in healthy controls (n = 48) revealed BRIP1 rs552752779 (MAF: 75% vs. 6.25%, OR 45.00, 95% CI 9.43-243.32), ERBB2 rs527779103 (MAF: 62.5% vs. 7.29%, OR 21.19, 95% CI 5.11-94.32), ERCC2 rs121913016 (MAF: 56.25% vs. 7.29%, OR 16.34, 95% CI 4.02-70.41), MSH6 rs2020912 (MAF: 56.25% vs. 1.04%, OR 122.13, 95% CI 12.29-2985.48) as risk factors for triple negative breast cancer.
|
30136158 |
2018 |